RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Clinical trials for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA explained in plain language.
Never miss a new study
Get alerted when new RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA trials appear
Sign up with your email to follow new studies for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for blistering skin diseases: drug targets antibodies to heal wounds
Disease control Not yet recruitingThis early-phase study tests whether the drug efgartigimod (VYVGART) can lower harmful collagen VII antibodies and improve wound healing in people with two rare blistering skin conditions: recessive dystrophic epidermolysis bullosa (RDEB) and epidermolysis bullosa acquisita (EBA)…
Matched conditions: RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Phase: PHASE1, PHASE2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Anti-Inflammatory drug may ease swallowing in rare skin disease
Symptom relief Not yet recruitingThis study investigates whether budesonide, an anti-inflammatory medication, can improve swallowing difficulties in people with dystrophic epidermolysis bullosa, a rare genetic condition that causes fragile skin and scarring. The researchers will review medical records of 15 pati…
Matched conditions: RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Phase: NA • Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
New cream aims to soothe butterfly skin in Late-Stage trial
Symptom relief Not yet recruitingThis Phase 3 study tests the safety of SD-101 cream (6% allantoin) in 80 people with epidermolysis bullosa, a condition that causes fragile, blistering skin. Participants must have completed a prior study (SD-007). The main goal is to track any side effects over time.
Matched conditions: RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Phase: PHASE3 • Sponsor: Paradigm Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC